ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO946

The Safety Profile and Impact of Remdesivir on Renal Function and Outcome in COVID-19 Infected Renal Allograft Recipients: A Retrospective Cohort Study From a Tertiary Care Hospital in Western India

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Patel, Mohan P., Apollo Specialty Hospitals Pvt Ltd, Nashik, Maharashtra, India
  • Goswami, Jitendra, Manipal Hospitals, Jaipur, Rajasthan, India
Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection has extremely impacted the transplant population. Remdesivir (RemD) has shown some promising results in coronavirus disease (COVID-19) pandemic though with low certitude. Literature in kidney transplant recipients (KTR) were still lacking at the time of ongoing pandemic situation.

Methods

This was a retrospective cohort of 52 moderate to severe COVID-19 positive KTR in a single center who received RemD as a part of COVID-19 management. No dose adjustments were done. The outcomes were measured as acute kidney injury (AKI) recovery; liver function tests abnormalities, other side effects; graft loss and all-cause mortality.

Results

The median (inter-quartile range) age of presentation was 47 (25-56) years. The duration from onset of symptoms to RemD initiation was 5 (4-9) days. Thirty seven (71.2%) cases received RemD on the day of admission. Thirty-nine (75%) cases were on oxygen support upon initiation of RemD. Thirty-two (61.5%) cases had acute kidney injury on admission. The median baseline, admission, and 28-day follow-up serum creatinine of the cohort were 1.5 (1.1-2.0), 2.4 (1.4-3.2), and 1.6 (1.04-2.2) mg/dl, respectively. A total of 12(23%) cases died in the study with 1 (1.9%) graft loss. All those cases that died were on oxygen therapy at the time of initiation of RemD. No significant liver dysfunction or any other major adverse events with the drug were observed.

Conclusion

RemD therapy is safe and clinically feasible in renal allograft recipients as seen in our cohort. Larger randomized clinical trials should be conducted to further explore the efficacy in renal allograft recipients.